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Adenosine suppresses immune responses through the A2A receptor (A2AR). This study investigated the interleukin 10 (IL-10)
genetic proﬁle and the expression of A2AR in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive
impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish diﬀerent forms
of cognitive decline. We analyzed the IL-10 genotype and the expression of A2AR in 41 subjects with AD, 10 with amnestic MCI
(a-MCI), 49 with multiple cognitive domain MCI (mcd-MCI), and 46 controls. There was a signiﬁcant linear increase in A2AR
mRNA levels and A2AR density from mcd-MCI to a-MCI, with intermediate levels being found in AD. The IL-10 AA genotype
frequency was 67% in a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls. These data suggest that the assessment of the
IL-10 genotype and the expression of A2AR in PBMCs may be a valuable means of diﬀerentiating between a-MCI and mcd-MCI.
1.Introduction
The purine ribonucleoside adenosine (Ado) is a natu-
rally occurring metabolite that is ubiquitously distributed
throughout the body as a metabolic intermediary. Ado accu-
mulates in the extracellular space at the site of inﬂammation
[1] in response to metabolic stress and cell damage, and
there is evidence that it could play a key role in preserving
homeostasis [2]. The physiological responses to Ado take
place as a result of the binding and activation of diﬀerent
transmembrane receptors: high-aﬃnity A1 receptor (A1R)
and A2AR, low-aﬃnity A2BR, or low-abundance A3R. A2AR
are found throughout the body, and an increasing wealth
of evidence supports the idea that they represent the major
immunoregulatory arm of the Ado receptor system, down-
regulating inﬂammation [3–7] and also preventing beta
amyloid (Aβ) induced synaptotoxicity [8].
A recent study showed that stimulation of A2ARr e p r e -
sents a crucial second signal in the production of IL-10, the
major anti-inﬂammatory cytokine [9].
Inﬂammation is accepted to be a feature of Alzheimer’s
disease (AD) [10, 11] and the pathogenesis of neurodegen-
eration has been at least in part attributed to the release of
proinﬂammatory cytokines from brain resident cells [12, 13]
and, althoughlessconsistently,fromperipheralcells[14, 15].
Recently, speciﬁc risk sets of pro-inﬂammatory and anti-
inﬂammatory alleles were found to be associated with AD
at diﬀerent ages of onset [16]. Such alleles also comprise the
−1082 polymorphism (G/A substitution) in the IL-10 gene
promoter region [17]. On the basis of these considerations,
we investigated (1)the expression of theA2ARgen ean dA 2AR
protein levels in the peripheral blood mononuclear cells
(PBMCs) of patients with mild cognitive impairment (MCI,
the preclinical state of dementia), patients with outright AD
andage-matchedcontrolswithoutcognitiveimpairmentand
(2) the relationship between the IL-10 geneticproﬁle and the
A2A phenotype, since A2AR regulates IL-10 production.
2.Materialsand Methods
2.1. Study Design. The study involved 41 AD patients (mean
age 79.47 ± 6.30 years), 46 non demented age- and gender-
matched healthy controls with similar educational levels
(mean age 79.98 ± 6.36 years), and 59 subjects with MCI
(mean age 78 ± 5.16 years). All of the patients were2 International Journal of Alzheimer’s Disease
Caucasians living in Northern Italy who were prospectively
enrolled from a larger population of outpatients attending
the Geriatric Unit of the Ospedale Maggiore IRCCS, Univer-
sity of Milan, Italy.
Probable AD was diagnosed using standard clinical
proceduresand DMSIVand NINCDS-ADRDAcriteria[18].
Functional status was assessed by means of the Activities of
Daily Living (ADL) and Instrumental Activities of Daily Liv-
ing(IADL)scalesand cognitiveperformance bymeans of the
Mini-Mental StateExamination (MMSE)and ofan extensive
neuropsychological evaluation. A computed tomography or
magnetic resonance imaging scancorroboratedthediagnosis
of AD.
The criteria for thediagnosis ofnormal cognitionwere as
follows:(1)noactiveneurologicalorpsychiatricdisorder;(2)
no ongoing medical problems or related treatments interfer-
ing with cognitive function; (3) a normal neurological exam;
(4) no psychoactive medications; (5) the ability to live and
function independently in the community.
The MCI subjects were divided into two groups on
the basis of their cognitive characteristics: amnestic MCI
(a-MCI, 10 patients) and multiple cognitive domain MCI
(mcd-MCI, 49 patients). The a-MCI subjects met the cri-
teria described by Petersen [19]: only memory impairment
(>1.5SD above age- and education-speciﬁc norms) with
no diﬃculties in any other area of cognitive functioning.
The mcd-MCI subjects were impaired in at least two
cognitive domains (>1SD below the mean of an age- and
education-matched population), their cognitive decline was
self-reported or reported by a reliable informant, but they
could not be diagnosed as having dementia. The cutoﬀ score
of 1SD (less than the threshold used for a-MCI) was selected
in order to ensure greater diagnostic sensitivity, albeit at
the expense of diagnostic speciﬁcity. In fact the presence
of more than one cognitive deﬁcit and frequent initial
IADL impairment may lead to mcd-MCI being mistaken for
dementia, and the less restrictive criterion of >1SD allows
their better diﬀerentiation [20].
Blood from all patients and controls was collected in the
morning between 8 and 9AM, after a 6-hour fast.
None of the patients or controls was on treatment
with dipyridamole or methylxanthines, and their caﬀeine
consumptionwasabout80mg/die(onecupofcoﬀee)orless.
The risk of possible inﬂammatory processes was mini-
mized by the fact that none of the subjects selected showed
any clinical signs of inﬂammation (their body temperature
was normal, and none of them had a concomitant inﬂam-
matory condition) and that they all had normal plasma
albumin, transferring, and C-reactive protein levels. All of
the subjects and their relatives gave their informed consent,
and the study protocol was approved by the University
Hospital’s Ethics Committee.
2.2. Apolipoprotein E (ApoE) Genotyping. Whole blood was
collected by means of a venipuncture into Vacutainers
(Becton Dickinson Co., Rutherford, NJ). Genomic DNA was
extracted using a previously described salting-out method
[21], and its concentration and purity were determined by
means of spectrophotometric analysis. The ApoE genotypes
were determined by means of the PCR ampliﬁcation of
a 234 base-pair fragment of exon 4 of the ApoE gene,
followed by digestion using Cfo1, as previously described
[22]. Restriction patterns were revealed by means of 4%
agarose gel electrophoresis.
2.3. Cytokine Genotyping. A polymerase chain reaction-
sequence-speciﬁc primers (PCR-SSP) method was employed
to assess IL-10 genotypes. The sequence in the promoter
region of the IL-10 (polymorphism −1082) gene was
ampliﬁed using the cytokine genotyping tray method (One
Lambda, Canoga Park, CA, USA); the human β-globin gene
was ampliﬁed as an internal control for the genomic DNA
preparation. PCR conditions were indicated by the One
Lambda PCR program (OLI-1), and the PCR products were
visualized by electrophoresis in 2.5% agarose gel.
2.4. A2AR mRNA Expression. PBMCs were separated by
density gradient using the Lympholyte-H kit (Cedarlane
Laboratories Limited, Canada), and total RNA was isolated
from 15 × 106 frozen cells using Chomczynski and Sacchi’s
m o d i ﬁ e dm e t h o d[ 23]. The concentration of total RNA
was quantiﬁed by means of spectrophotometry, and 2ug
of RNA were reverse-transcribed using the M-MLV Reverse
Transcriptase System and oligo (dT) (Clontech, Italy). The
resulting cDNA was real-time ampliﬁed in a ﬁnal volume of
50μL. The mix contained 25μL of 2x iQ SYBR Green Super-
mix (dNTPs, iTaq, and MgCl2; Bio-Rad, Italy) and 300mM
of each primer (A2AR: Forward 5 -GGCTGCCCCTACACA-
TCATC-3 ,R e v e r s e5  -GCCAGGTACATGAGCCAGAGA-
3 ). PCR was performed using a Chromo 4 instrument and
analyzed using Opticon Monitor 2 (Celbio, Italy). All of the
reactions were performed in duplicate, with thermal cycling
conditionsof10minat95◦Cfollowedby40cyclesat95◦Cfor
15s, 56◦C for 40s, and 72C◦ for 30s, with a ramp of 5C◦/s.
Real-time PCR for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was performed simultaneously (GAPDH:
Forward 5 -ATTCCACCCATGGCAAATTC3 , Reverse 5 -
TGGGATTTCCATTGATGACAAG-3 ).
T h er e l a t i v eq u a n t i ﬁ c a t i o no fA 2A mRNA expression was
carried out by using the comparative cycle threshold (Ct)
method and the formula normalization ratio (NR) = 2−ΔΔCt.
The ΔCt value of each sample was calculated as the Ct of
the target gene minus the Ct of GAPDH, and then the ΔΔCt
value was obtained as the diﬀerence between the ΔCt of the
sample and the ΔCt of the calibrator [24]. According to this
formula,thenormalization ratio ofthecalibratorin each run
is 1. The calibrator in each sample run was the same RNA
extracted from a single healthy control and stored at −80◦C.
2.5. A2A Receptor Densities. PBMCs from 10 a-MCI, 27
AD, 20mcd-MCI, and 20 controls subjects were available
for protein expression. The cells were lyzed in Triton X-
114 Tris buﬀer with a protease inhibitors cocktail (Sigma,
Italy). Brieﬂy, after centrifugation (12,000rpm at 4◦C), the
supernatant was loaded onto a sucrose cushion buﬀer andInternational Journal of Alzheimer’s Disease 3
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Figure 1: A2AR mRNA levels (mean values ± standard error) in
PBMCs from 41AD, 10 a-MCI, 49mcd-MCI, and 46 control (CT)
subjects quantiﬁed by the 2−ΔΔCt method. Bonferroni post hoc: a-
MCI versus controls and mcd-MCI patients (P<. 05).
incubated at 37◦C for 3min. The samples were then cen-
trifuged again in orderto obtaintwo phases, and 10μgo ft h e
totalproteinextractsoftheaqueousphasewere denaturedby
boiling for 10min at 100◦C in Laemmli SDS loading buﬀer,
reduced with 5% mercaptoethanol and separated by 10%
SDSpolyacrylamide gel [25]. Electrophoresis was performed
at 20–30mA for 110min, and the proteins were blotted onto
a0 . 4 5 μm polyvinylidene ﬂuoride membrane (Immobilon,
Millipore, Italy) at 90V for 90min at 4◦C; after transfer,
nonspeciﬁc binding was blocked for 120min using 5% milk
in phosphate buﬀer saline with 0.1% Tween 20 (PBST). The
membranes were incubated overnight with polyclonal rabbit
antihuman A2AR antibody (1:2000) (Calbiochem, Ger-
many) and goat antirabbit IgG HRP (1:2000) (Bio-Sciences,
Italy) and chemiluminescent substrate (Bio-Sciences, Italy).
Puriﬁed A2AR (Chemicon, Italy) was loaded as positive
control(onemajorbandofabout45kDa)andtoevaluatethe
interassay variability (less than 10% in all experiments). To
account for protein loading variation [26], the membranes
were stripped and then reprobed with monoclonal anti-
human GAPDH (1:8000) (Chemicon International, USA)
and rabbit antimouse IgG-HRP (1:8000) (Sigma, Italy) and
chemiluminescent substrate. All experiments were run in
duplicate. Membranes were scanned, and the density of
the protein bands was estimated by IM1D software (Bio-
Sciences,Italy).The results were expressed asArbitrary Units
(A2AR/ G A P D Hr a t i o ) .
2.6. Statistical Analysis. The statistical analysis was per-
formed using the SPSS statistical package (SPSS version
17, Chicago, IL). An outlier analysis was conducted before
the comparisons. The diﬀerences in mRNA and protein
levels, expressed as mean values ± standard error (SE),
were calculated using the one-way analysis of variance
followed by Bonferroni’s post hoc test in the case of multiple
comparisons. The genotype and allele distributions were
evaluated using Pearson’s χ2.AP value <.05 was considered
statistically signiﬁcant.
3.Results
3.1. Distribution of the ApoE Genotype. The frequency of
ApoE ε4 was 50% in a-MCI patients, 44% in AD patients,
38.8% in mcd-MCI patients, and 11% in control subjects.
These frequencies are similar to those already reported [27].
3.2. Distribution of the IL-10 Genotype. The distribution
of the −1082 (G/A) polymorphism was similar to that
previously described [22]. In particular, the frequency of the
AAgenotype,associated withahigherriskofAD,was67%in
a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls,
respectively (P = .014).
3.3. A2A Gene Expression and Receptor Densities. The qPCR
analysis (Figure 1) revealed signiﬁcantly higher (P<. 05)
A2ARm R N Al e v e l si np a t i e n t sw i t ha - M C I( 3 . 7 7± 1.02)
than in controls (2.12 ± 0.21) and in patients with mcd-
MCI (1.42 ± 0.12). It is interesting to note that also A2AR
density (Figures 2 and 3), expressed as A2AR/GAPDH ratio,
was signiﬁcantly higher in patients with a-MCI (0.71 ± 0.17)
than in controls (0.62 ± 0.05) and in patients with mcd-
MCI (0.43 ± 0.05). Both gene expression (2.50 ± 0.22) and
density (0.50 ± 0.06) of the A2AR in PBMCs of AD patients
were not signiﬁcantly diﬀerent from those of the controls
(Figures 1 and 3). When the data were stratiﬁed according
t ot h ep r e s e n c eo ra b s e n c eo ft h eA p o Eε4 allele, A2ARg e n e
expression and receptor density were similar both in the ε4
carriers and noncarriers.
Interestingly, the carriers of the G allele of the −1082
IL-10 polymorphism (GG and GA) showed the lowest level
of A2AR mRNA, independently of cognitive status (1.7 ±
0.13 and 2.7 ± 0.36, in carriers versus noncarriers, resp.;
P = .002).
4.Discussion
The results of this observational study show that the level
of A2AR expression is higher in PBMCs from a-MCI than
from mcd-MCI. When the data were stratiﬁed according to
the presence or absence of the ApoE ε4 allele, A2ARg e n e
expression and receptor density were similar both in the ε4
carriers and noncarriers. This indicates that the ApoE ε4
allele, a major genetic risk factor for late onset sporadic AD
[28–30], does not appear to participate in the modulation of
this gene.
The small number of patients and the lack of A2AR
measurements in the cerebrospinal ﬂuid do not allow us to
draw any conclusion on the relationship between peripheral
A2AR modulation and Ado metabolism in the brain. Yet the
ﬁnding of an upregulation of A2ARi nt h eP B M C so fs u b j e c t s
w i t ha - M C Ib u tn o tw i t hA Ds e e m st oﬁ tw i t ht h er e s u l t so fa
previous study [31] demonstrating that in the brain cortex
the increased expression of both A2ARa n dA 1Ri sm a i n l y
an early event in the pathogenesis of AD [32]. One possible
explanation of our ﬁnding is that a second event, which
is required for the development of AD in a-MCI subjects,
subsequently intervenes to downregulate A2AR expression4 International Journal of Alzheimer’s Disease
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Figure 2: Paradigmatic example of the Western blot analysis of the A2AR densities in PBMC extract from one subject belonging to the AD,
a-MCI, mcd-MCI, or control (CT) group, run in duplicate.
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Figure 3:A2AR densities (mean values ± standard error) in PBMCs
from 27AD, 10 a-MCI, 20mcd-MCI, and 20 control (CT) subjects
expressed as A2AR/GAPDH ratio. Bonferroni post hoc: a-MCI
versus controls and mcd-MCI patients (P<. 05).
in PBMCs by a negative feedback mechanism and thus
counteracts the anti-inﬂammatory eﬀect of Ado. Therefore,
within the multifactorial pathogenesis of AD, there may be a
speciﬁc time-window for the involvementof the Ado system.
It is still unclear whether and how peripheral inﬂamma-
tion acts on the AD brain; there are, however, several lines of
evidence in favour of its contribution to the disease process.
First, AD patients who also have short-term peripheral
infections undergo a sudden decline in cognitive status
[33]; second, plasma levels of alpha1-antichymotrypsin,
interleukin-6,andC-reactive proteinare increased beforethe
clinical onset of various types of dementia, including AD
[34]; third, the signs of inﬂammation observed in the brain
of AD patients are comparable to those seen in peripheral
inﬂammatory reactions and are likely to have a strong
cytotoxic eﬀect on neurons [35]; fourth, individuals who
have levels of Aβ and tau aggregates similar to those of AD
patients,butyetdonotdevelopdementia,exhibitlessersigns
of inﬂammation [36].
The lack of a signiﬁcant diﬀerence in A2AR expression
between AD subjects and controls is consistent with the data
of former studies showing that also cytokine production
is increased in PBMCs of MCI but not AD subjects [15,
37]. Thus, a peripheral inﬂammatory response seems to be
involved only in the early stage of the disease and appears to
be lost in overt AD.
In our patients the IL-10 low-producer AA genotype,
which also seemed to be associated with the highest mRNA
levels of A2AR, was more frequent in the a-MCI group. IL-
10, a powerful anti-inﬂammatory cytokine, maps to chro-
mosome 1 between 1q31 and 1q32, is highly polymorphic,
and its production is correlated to biallelic polymorphisms
at position−1082 (G to A). In previous studies, we not
only described a signiﬁcantly greater prevalence of the IL-
10 −1082 AA low-producer genotype in subjects with overt
AD as well as in subjects with a-MCI who eventually
progressed to AD [37], but we also found a reduced IL-
10 generation in PBMCs from these patients after Aβ
stimulation [22]. Interestingly a report on centenarians, in
whom an exceptionally long lifespan is held to reﬂect the
combined inﬂuence of lifestyle choices and genetic factors,
demonstrated that longevity is signiﬁcantly associated with
the IL-10 high-producer GG genotype [38].
Limitations of this observational study are the small
number of enrolled subjects, and that it was possible to
evaluate the correlation between the IL-10 genetic proﬁle
and gene expression only for A2AR. However, if the ﬁndings
of this study are conﬁrmed by a prospective study with a
larger number of subjects, they can have a potential clinical
applicationand providefurther insight into thepathogenesis
of AD. The evaluation of A2AR expression in the periphery
could be a valuable means to diﬀerentiate mcd-MCI and a-
MCI subjects. Also, it could be hypothesized that the overallInternational Journal of Alzheimer’s Disease 5
risk of developing AD is governed by a multifactorial “sus-
ceptibility proﬁle” related not only to gene variants but also
to alterations in the signalling pathway of molecules, such as
adenosine, that play a key role in neuroinﬂammation.
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